There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cardiol Therapeutics (CRDL – Research Report), Biogen (BIIB – Research Report) and Nurix Therapeutics (NRIX – Research Report) with bullish sentiments.
Cardiol Therapeutics (CRDL)
In a report issued on February 16, Edward Nash from Canaccord Genuity maintained a Buy rating on Cardiol Therapeutics, with a price target of $6.00. The company’s shares closed last Friday at $1.43, close to its 52-week high of $1.48.
According to TipRanks.com, Nash is a 2-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cardiol Therapeutics with a $6.00 average price target.
See the top stocks recommended by analysts >>
Biogen (BIIB)
In a report issued on February 16, Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on Biogen, with a price target of $305.00. The company’s shares closed last Friday at $219.08, close to its 52-week low of $217.53.
According to TipRanks.com, Kulkarni is a 4-star analyst with an average return of
Biogen has an analyst consensus of Moderate Buy, with a price target consensus of $298.96, representing a 35.2% upside. In a report issued on February 6, Jefferies also maintained a Buy rating on the stock with a $300.00 price target.
Nurix Therapeutics (NRIX)
In a report released today, Matthew Biegler from Oppenheimer maintained a Buy rating on Nurix Therapeutics, with a price target of $25.00. The company’s shares closed last Friday at $9.87.
According to TipRanks.com, Biegler is a 3-star analyst with an average return of
Nurix Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $25.40, implying a 174.6% upside from current levels. In a report issued on February 5, Piper Sandler also maintained a Buy rating on the stock with a $35.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CRDL:
